Pacer Advisors
PGNX

Pacer Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Pacer Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,272
Closed -$102K – 1156
2018
Q3 		$102K Buy
+16,272
New +$125K ﹤0.01% 1091
2018
Q1 		– Sell
-2,400
Closed -$14K – 1169
2017
Q4 		$14K Buy
+2,400
New +$14.6K ﹤0.01% 1126

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Pacer Advisors's PGNX Position: Q4 2018 in Review

Pacer Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 16,272 shares — an estimated $102K sold.

Pacer Advisors first reported a position in PGNX in Q4 2017 and held it in 2 quarters. The position peaked at $102K in Q3 2018. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

  • Pacer Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Pacer Advisors sold 16,272 Progenics Pharmaceuticals Inc shares in Q4 2018, an estimated $102K.
  • Pacer Advisors first reported a position in Progenics Pharmaceuticals Inc in Q4 2017 and held it in 2 quarters.
  • Pacer Advisors's Progenics Pharmaceuticals Inc position peaked at $102K in Q3 2018.
  • 150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Pacer Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.